MEI Mediclinic half-year group results for period ended 30 September 2020 Mediclinic International plc Incorporated in England and Wales Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 South African income tax number: 9432434182 (Mediclinic, or the Company, or the Group) MEDICLINIC HALF-YEAR GROUP RESULTS FOR PERIOD ENDED 30 SEPTEMBER 2020 DELIVERING A ROBUST FIRST-HALF OPERATING PERFORMANCE WHILE CONTINUING STRATEGY EXECUTION GROUP FINANCIAL RESULTS - Revenue down 7% to #1 411m; down 5% in constant currency; significantly impacted by April 2020 due to sudden onset of COVID-19 restrictions - Adjusted EBITDA at #171m down 32% in both reported and constant currency terms reflecting a mostly fixed employee cost base - Adjusted operating profit down 54% at #66m; reported operating profit down 57% to #64m - Reported earnings of #15m (1H20: #109m), including equity accounted loss of Spire - Adjusted earnings per share down 77% at 2.3 pence; reported earnings per share 2.0 pence (1H20: 14.8 pence) - Headline earnings per share 2.4 pence (1H20: 14.2 pence) - Cash conversion at 42% of adjusted EBITDA (1H20: 98%) largely due to increased debtor balances caused by lower collections compared with earlier in the period - Cash and available facilities of #661m (FY20: #518m) - Previously announced covenant test waivers in place - Dividend remains suspended as part of the Group's broad response to maintaining its liquidity position (1H20: 3.20 pence) BOARD CHANGES The following changes to the Board and its committees have occurred and been announced since the financial year-end: As announced on 24 July 2019 and 22 July 2020, Dr Edwin Hertzog retired as a non-executive director and Chair of Mediclinic at the conclusion of the Company's 2020 Annual General Meeting on 22 July 2020. Dr Hertzog also stepped down as Chair of the Nomination Committee, as Chair of the Investment Committee, and as a member of the Clinical Performance and Sustainability Committee from that date. Dr Hertzog was succeeded as Chair of Mediclinic by Dame Inga Beale on 22 July 2020, following her appointment on 26 March 2020 as an independent non-executive director and Chair Designate. As announced on 22 July 2020, Dame Inga also succeeded Dr Hertzog as Chair of the Nomination Committee with effect from that date. As further announced on 22 July 2020, Mr Steve Weiner was appointed as an independent non- executive director and as a member of both the Audit and Risk Committee and the Clinical Performance and Sustainability Committee with effect from 22 July 2020. The Board has also agreed to certain additional changes to the membership of its committees as part of ongoing succession planning, as set out below: Investment Committee Mr Jannie Durand was appointed as Chair of the Investment Committee and Dame Inga was appointed as a member of the Investment Committee with effect from 1 September 2020. Remuneration Committee Mr Weiner was appointed as a member of the Remuneration Committee with effect from 11 November 2020. DIVIDEND POLICY The Groups existing dividend policy is to target a pay-out ratio of between 25% and 35% of adjusted earnings. The Board may revise the policy at its discretion. As part of the Groups response to maintaining its liquidity position through the COVID-19 crises and to maximise its support in combatting the pandemic, the Board has taken the prudent and appropriate decision to suspend the dividend. FURTHER INFORMATION The contents of this short-form announcement are the responsibility of the Board of Directors of the Company. This announcement represents a summary of the information contained in the unabridged results announcement. Any investment decisions by investors and/or shareholders should be based on a consideration of the unabridged announcement. The unabridged announcement can be accessed on the following JSE link: https://senspdf.jse.co.za/documents/2020/JSE/ISSE/MEIE/MEIHY21.pdf The announcement is also published on www.mediclinic.com and available for inspection at the registered office of the Company and the offices of the Companys sponsor at no charge, during normal business hours. CORPORATE INFORMATION LISTINGS The Companys primary listing is on the London Stock Exchange in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia. DIRECTORS Inga Beale DBE (ind ne) (Chair) (British), Dr Ronnie van der Merwe (Group Chief Executive Officer) (South African), Jurgens Myburgh (Group Chief Financial Officer) (South African), Alan Grieve (Senior Independent Director) (British and Swiss), Dr Muhadditha Al Hashimi (ind ne) (Emirati), Jannie Durand (ne) (South African), Dr Felicity Harvey CBE (ind ne) (British), Danie Meintjes (ne) (South African), Dr Anja Oswald (ind ne) (Swiss), Trevor Petersen (ind ne) (South African), Tom Singer (ind ne) (British), Steve Weiner (ind ne) (American), Pieter Uys (alternate to Jannie Durand) (South African) COMPANY SECRETARY Link Company Matters Limited (previously named Capita Company Secretarial Services Limited) REGISTERED OFFICE Mediclinic International plc 6th Floor, 65 Gresham Street London, EC2V 7NQ, United Kingdom Tel: +44 20 7954 9569 Fax: +44 20 7954 9886 Email: email@example.com Website: www.mediclinic.com TOLL-FREE ETHICS LINES Switzerland and South Africa Tel: 0800 005 316 UAE Tel: 800 1 55000 REGISTRAR/TRANSFER SECRETARIES UK United Kingdom Computershare Investor Services PLC SOUTH AFRICA Computershare Investor Services (Pty) Ltd NAMIBIA Transfer Secretaries (Pty) Ltd CORPORATE ADVISORS AUDITOR PricewaterhouseCoopers LLP, London CORPORATE BROKER AND SPONSORS UK Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank South Africa JSE sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited) Namibia NSX sponsor: Simonis Storm Securities (Pty) Ltd 12 November 2020 Date: 12-11-2020 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.
12 Nov 2020